TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19101790

Group type: EXPERIMENTAL
Intervention: Combination of targeted agents (specific agents not mentioned)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endocrine pathway inhibition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vascular endothelial growth factor pathway inhibition
Number of subjects: 0
Study: 16879516

Group type: EXPERIMENTAL
Intervention: Fiberoptic bronchoscope (FOB)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Direct laryngoscope (DLS)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both FOB and DLS
Number of subjects: 43
Study: 12596015

Group type: EXPERIMENTAL
Intervention: Interferon-beta 1a (44 microg subcutaneous Rebif once weekly)
Number of subjects: 717
Study: 10854087

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS, 30 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Lacidipine, 4 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 9180716

Group type: EXPERIMENTAL
Intervention: Textured saline-filled implants
Number of subjects: 21

Group type: COMPARATOR
Intervention: Smooth saline-filled implants
Number of subjects: 21
Study: 1524921

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen daily for 2 years
Number of subjects: 2230

Group type: COMPARATOR
Intervention: Control (perioperative cyclophosphamide)
Number of subjects: 2230

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen
Number of subjects: 2230
Study: 4091243

Group type: EXPERIMENTAL
Intervention: M-mode echocardiography
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Two-dimensional echocardiography
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pulse Doppler echocardiography
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Halothane, enflurane, isoflurane (MAC 1.0 and 1.5)
Number of subjects: 30
Study: 29369673

Group type: EXPERIMENTAL
Intervention: Text-message intervention (Message 1: personalized normative feedback, Message 2: protective behavioral strategies)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Text-message intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 200
Study: 28436722

Group type: EXPERIMENTAL
Intervention: High intensity interval exercise training (36 sessions)
Number of subjects: 20
Study: 24552352

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 46

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 46
Study: 22619366

Group type: EXPERIMENTAL
Intervention: 3 g of gluten/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 7.5 g of gluten/day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 3 g or 7.5 g of gluten/day
Number of subjects: 20
Study: 21071509

Group type: EXPERIMENTAL
Intervention: 0.5-Ratio (4.5% fructose, 9% maltodextrin)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 0.8-Ratio (6% fructose, 7.5% maltodextrin)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 1.25-Ratio (7.5% fructose, 6% maltodextrin)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 10
Study: 18298234

Group type: EXPERIMENTAL
Intervention: Self-affirmation
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 57
Study: 16568428

Group type: EXPERIMENTAL
Intervention: Long TE spectroscopy using LCModel technique at 1.5 T
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Long TE spectroscopy using LCModel technique at 3 T
Number of subjects: 25

Group type: COMPARATOR
Intervention: Long TE spectroscopy using LCModel technique
Number of subjects: 25
Study: 12817159

Group type: EXPERIMENTAL
Intervention: Paroxetine (10-60 mg/day)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 76

Group type: COMPARATOR
Intervention: Paroxetine and Placebo
Number of subjects: 76
Study: 10591284

Group type: EXPERIMENTAL
Intervention: Medication management
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Combined treatment (medication management + intensive behavioral treatment)
Number of subjects: 579

Group type: COMPARATOR
Intervention: Behavioral treatment
Number of subjects: 579

Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 579
Study: 8606209

Group type: EXPERIMENTAL
Intervention: Terbutaline 0.5 mg subcutaneously 6 hourly for 48 hours (group T)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Terbutaline (group T)
Number of subjects: 22
Study: 2008863

Group type: EXPERIMENTAL
Intervention: 420‐kcal/d liquid diet (n = 12)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1200‐kcal/d balanced diet (n = 8)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1200‐kcal/d diet (after 16 weeks for both groups)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (6 obese nondieters)
Number of subjects: 20
Study: 7036765

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine in combination with chloroquine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chloroquine alone
Number of subjects: 0
Study: 31167540

Group type: EXPERIMENTAL
Intervention: Stiripentol
Number of subjects: 0
Study: 30184562

Group type: EXPERIMENTAL
Intervention: MetS risk score model
Number of subjects: 4395

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 4395

Group type: EXPERIMENTAL
Intervention: FPG
Number of subjects: 4395

Group type: EXPERIMENTAL
Intervention: DBP
Number of subjects: 4395

Group type: EXPERIMENTAL
Intervention: HDL-C
Number of subjects: 4395
Study: 26767971

Group type: EXPERIMENTAL
Intervention: Traditional Malay massage
Number of subjects: 66

Group type: COMPARATOR
Intervention: Relaxation position (Control)
Number of subjects: 66
Study: 24262059

Group type: EXPERIMENTAL
Intervention: Kneeling position
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Footstool position
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standing position
Number of subjects: 38
Study: 22278425

Group type: EXPERIMENTAL
Intervention: Medical treatment with pasireotide, cabergoline, and ketoconazole over 80 days
Number of subjects: 17

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 17
Study: 21125810

Group type: EXPERIMENTAL
Intervention: Test formulation (250 mg alpha-methyldopa tablet)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Reference formulation (250 mg alpha-methyldopa tablet)
Number of subjects: 12
Study: 17640790

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (AG/GG carriers)
Number of subjects: 102
Study: 15831508

Group type: EXPERIMENTAL
Intervention: Misoprostol (n=79)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Curettage (n=75)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Misoprostol (successful)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Misoprostol (unsuccessful)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 154
Study: 11908635

Group type: EXPERIMENTAL
Intervention: Bovine lactoferrin (bLf) gargles (100 mg t.i.d.) + oral erythromycin (500 mg t.i.d.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Oral erythromycin (500 mg t.i.d.)
Number of subjects: 12
Study: 10408752

Group type: EXPERIMENTAL
Intervention: Care co-ordination
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 77
Study: 7744989

Group type: EXPERIMENTAL
Intervention: Methimazole and thyroxine for a second year (160 patients)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Methimazole alone for a second year (35 patients)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Combined therapy (methimazole and thyroxine)
Number of subjects: 330
Study: 2033780

Group type: EXPERIMENTAL
Intervention: thiopentone/suxamethonium (Group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: thiopentone/pancuronium (Group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control values
Number of subjects: 40
Study: 7305036

Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 64
Study: 31441853

Group type: EXPERIMENTAL
Intervention: Light alcohol drinkers
Number of subjects: 1472

Group type: EXPERIMENTAL
Intervention: Individuals with high regular physical activity
Number of subjects: 1472

Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 1472

Group type: EXPERIMENTAL
Intervention: Individuals aged >65 years
Number of subjects: 1472

Group type: EXPERIMENTAL
Intervention: Individuals with higher body mass index, presence of metabolic syndrome, and smoking
Number of subjects: 1472
Study: 28503781

Group type: EXPERIMENTAL
Intervention: Upadacitinib (3 mg) after high-fat meal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Upadacitinib (3 mg) with ketoconazole (400 mg once daily for 6 days)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Upadacitinib (12 mg) with rifampin (600 mg once daily for 9 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Upadacitinib (12 mg) with single dose of rifampin
Number of subjects: 24
Study: 26370687

Group type: EXPERIMENTAL
Intervention: Responsiveness Index (RI) monitoring
Number of subjects: 74
Study: 23353791

Group type: EXPERIMENTAL
Intervention: BIS-guided protocol
Number of subjects: 2949
Study: 21401909

Group type: EXPERIMENTAL
Intervention: Intravitreal injection of 0.05 ml anti-vascular endothelial growth factor agents
Number of subjects: 40
Study: 19786265

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents
Number of subjects: 22

Group type: COMPARATOR
Intervention: Zotarolimus-eluting stents
Number of subjects: 22
Study: 17156893

Group type: EXPERIMENTAL
Intervention: Glycerol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide
Number of subjects: 0
Study: 12607857

Group type: EXPERIMENTAL
Intervention: Transbond Plus (TBP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (CSE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etch & Prime 3.0 (EP3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acid-etched (AE)
Number of subjects: 0
Study: 10911572

Group type: EXPERIMENTAL
Intervention: Zona manipulated blastocyst stage transfers (n = 24)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Zona intact blastocyst stage transfers (n = 22)
Number of subjects: 46
Study: 9208536

Group type: EXPERIMENTAL
Intervention: Kuangquan 851 Oral Liquor type R
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Kuangquan 851 Oral Liquor type Y
Number of subjects: 303

Group type: COMPARATOR
Intervention: Qing Chun Bao Oral Liquor
Number of subjects: 303
Study: 1339081

Group type: EXPERIMENTAL
Intervention: 10 g fiber as wheat bran (WB)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 30 g fiber as wheat bran (WB)
Number of subjects: 34

Group type: COMPARATOR
Intervention: 10 g fiber as vegetable fiber (VF)
Number of subjects: 34

Group type: COMPARATOR
Intervention: 30 g fiber as vegetable fiber (VF)
Number of subjects: 34
Study: 3914314

Group type: EXPERIMENTAL
Intervention: Temporal artery constriction feedback
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Finger temperature feedback
Number of subjects: 22

Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 22
Study: 3481821

Group type: EXPERIMENTAL
Intervention: Propranolol and sulindac
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Propranolol and piroxicam
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Verapamil and sulindac
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Verapamil and piroxicam
Number of subjects: 25

Group type: COMPARATOR
Intervention: Propranolol and placebo
Number of subjects: 25
Study: 31788819

Group type: EXPERIMENTAL
Intervention: Verbal feedback on performance during meal preparation sessions with an occupational therapist
Number of subjects: 36

Group type: COMPARATOR
Intervention: Experiential feedback only (control condition) during meal preparation sessions
Number of subjects: 36
Study: 29756653

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ethanol (control)
Number of subjects: 20
Study: 28086906

Group type: EXPERIMENTAL
Intervention: Community-based lifestyle intervention (health promotion package including an information booklet, education sessions, walking group, and resistance band)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Standard advice (one session)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Community-based lifestyle intervention (health promotion package)
Number of subjects: 377
Study: 26164422

Group type: EXPERIMENTAL
Intervention: Multivitamins/minerals (MVM)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Multivitamins/minerals plus choline
Number of subjects: 367

Group type: COMPARATOR
Intervention: None (control group)
Number of subjects: 367
Study: 23586801

Group type: EXPERIMENTAL
Intervention: estradiol valerate/dienogest (E2V/DNG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 20496094

Group type: EXPERIMENTAL
Intervention: 64 MDCT scans performed with oral and intravenous contrast
Number of subjects: 303

Group type: COMPARATOR
Intervention: 64 MDCT scans performed solely with intravenous contrast
Number of subjects: 303
Study: 18206918

Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride 0.2 mg daily for 12 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Naftopidil 50 mg daily for 12 weeks
Number of subjects: 61
Study: 16401650

Group type: EXPERIMENTAL
Intervention: Amitriptyline 25mg
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Amitriptyline 25mg after 2 weeks
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo after 2 weeks
Number of subjects: 7
Study: 14556878

Group type: EXPERIMENTAL
Intervention: Tirofiban before primary angioplasty
Number of subjects: 61

Group type: COMPARATOR
Intervention: Glycoprotein IIb/IIIa inhibitors after initial coronary angiography
Number of subjects: 61
Study: 10950233

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (1000 microg daily for 7 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intravenous fluticasone propionate (1000 microg)
Number of subjects: 24
Study: 8643221

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 250 mg/m2, followed by L-folinic acid (LFA) 250 mg/m2 and 5-fluorouracil (FU) 600 mg/m2
Number of subjects: 21

Group type: COMPARATOR
Intervention: Methotrexate (MTX) 500 mg/m2, followed by L-folinic acid (LFA) 250 mg/m2 and 5-fluorouracil (FU) 600 mg/m2
Number of subjects: 21
Study: 1729814

Group type: EXPERIMENTAL
Intervention: Metoprolol (50 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6382640

Group type: EXPERIMENTAL
Intervention: Short-course chemotherapy for silicotuberculosis
Number of subjects: 94
Study: 31707985

Group type: EXPERIMENTAL
Intervention: Total hip replacement surgery
Number of subjects: 22
Study: 30554423

Group type: EXPERIMENTAL
Intervention: Fathers with high and medium inhibitory control (IC)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Fathers with low inhibitory control (IC)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Fathers' PTSD symptoms
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Inhibitory control (IC) skills
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Indirect effect of trauma exposure on parenting measures through PTSD
Number of subjects: 181
Study: 27488474

Group type: EXPERIMENTAL
Intervention: Nurse-Family Partnership plus existing services
Number of subjects: 1040

Group type: COMPARATOR
Intervention: Existing services
Number of subjects: 1040
Study: 24308845

Group type: EXPERIMENTAL
Intervention: Social cognitive theory, theory of planned behaviour, protection motivation theory
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Self-report PA
Number of subjects: 287
Study: 22677752

Group type: EXPERIMENTAL
Intervention: Combination of reamberin and cycloferon
Number of subjects: 73

Group type: COMPARATOR
Intervention: Traditional treatment
Number of subjects: 73
Study: 19841156

Group type: EXPERIMENTAL
Intervention: Escitalopram 5, 10, 15, or 20 mg daily for a minimum of 32 weeks
Number of subjects: 172
Study: 18633463

Group type: EXPERIMENTAL
Intervention: Oral-B Vitality Pro White power toothbrush
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dental prophylaxis followed by ADA reference manual toothbrush
Number of subjects: 0
Study: 16141449

Group type: EXPERIMENTAL
Intervention: Integrated treatment
Number of subjects: 547

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 547
Study: 11844946

Group type: EXPERIMENTAL
Intervention: Computerized mental stressor
Number of subjects: 15

Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control
Number of subjects: 15
Study: 10894434

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 20
Study: 8803304

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 to 30 mg/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Imipramine (100 to 125 mg/day)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 35
Study: 1376306

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (bleomycin 10 mg/m2/day, methotrexate 120 mg/m2, folinic acid, 5-fluorouracil 600 mg/m2, cisplatin 120 mg/m2)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Locoregional treatment alone (control group)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Number of subjects: 131
Study: 3934685

Group type: EXPERIMENTAL
Intervention: Intravenous pindolol (0.0256 mg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Submaximal exercise
Number of subjects: 6
Study: 30644999

Group type: EXPERIMENTAL
Intervention: Nurse-led decentralized ART treatment program
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Individualized case management approach
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Combination of nurse-led decentralized ART and individualized case management
Number of subjects: 800

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 800
Study: 29805112

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 54

Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 54

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 54
Study: 26974227

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 78

Group type: COMPARATOR
Intervention: Gatifloxacin
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Gatifloxacin (fluoroquinolone-resistant organisms)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Gatifloxacin (susceptible organisms)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Gatifloxacin (intermediately resistant organisms)
Number of subjects: 78
Study: 25328284

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) 80 ppm throughout the operation
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at the beginning and end of the operation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (nitrogen, N2) throughout the operation
Number of subjects: 45
Study: 22971854

Group type: EXPERIMENTAL
Intervention: Bioactive glass
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (without bioactive glass)
Number of subjects: 12
Study: 20828223

Group type: EXPERIMENTAL
Intervention: Bedtime administration of amlodipine-olmesartan
Number of subjects: 31

Group type: COMPARATOR
Intervention: Morning administration of amlodipine-olmesartan
Number of subjects: 31
Study: 18405399

Group type: EXPERIMENTAL
Intervention: Galantamine (intervention in the VISTA study)
Number of subjects: 130
Study: 15665326

Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 12612246

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 16

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 16
Study: 10521860

Group type: EXPERIMENTAL
Intervention: Cholesterol reduction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Weighted normal errors regression and random effects logistic regression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methods allowing for an additive component of residual heterogeneity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Restricted maximum likelihood estimator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Binomial model for observed proportions
Number of subjects: 0
Study: 7562763

Group type: EXPERIMENTAL
Intervention: Group physical therapy (weekly sessions)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Daily exercises at home
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Low impact fitness
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 207

Group type: COMPARATOR
Intervention: Controls (for FM)
Number of subjects: 207
Study: 1976580

Group type: EXPERIMENTAL
Intervention: Combined administration of 150 mg of roxatidine and 50 mg of pirenzepine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 150 mg of roxatidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control placebo group
Number of subjects: 0
Study: 7387018

Group type: EXPERIMENTAL
Intervention: High-dose theophylline (17 to 22 micrograms/mL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-dose theophylline (9.0 to 12.5 micrograms/mL)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31529691

Group type: EXPERIMENTAL
Intervention: Combined tDCS and WMT
Number of subjects: 201

Group type: COMPARATOR
Intervention: Sham tDCS and WMT
Number of subjects: 201

Group type: COMPARATOR
Intervention: tDCS and control cognitive training (CCT)
Number of subjects: 201
Study: 27746068

Group type: EXPERIMENTAL
Intervention: PPBS monitoring
Number of subjects: 240

Group type: COMPARATOR
Intervention: FBS monitoring
Number of subjects: 240
Study: 25847558

Group type: EXPERIMENTAL
Intervention: Dance group
Number of subjects: 46
Study: 23963662

Group type: EXPERIMENTAL
Intervention: Leaflet Self-Reading (LSR)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Computer-Assisted Instruction (CAI)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Individual Counseling (combined with LSR or CAI)
Number of subjects: 321
Study: 21107937

Group type: EXPERIMENTAL
Intervention: Intrathecal infusion of morphine
Number of subjects: 30